Metastatic Or Refractory Advanced Solid Tumors
INTSIntensity TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for INT230-6 (Intratumoral Cytotoxic) in Metastatic Or Refractory Advanced Solid Tumors. The expected timing is based on the latest available company guidance and may change.
11/06/25:- Peer-reviewed Phase 1/2 IT-01 study manuscript for metastatic or refractory advanced solid tumors was published with detailed efficacy and safety results; no future clinical or regulatory catalyst for this program was specified. 03/24/26:- New U.S. patent issued Dec 2025 for INT230-6. Completed Ph1/2 NCT03058289 reiterated. 03/27/26:- IT-01 eBioMedicine paper: 75% disease control, 11.9-month median OS, better outcomes when dosing >40% tumor burden. 05/07/26:- PR No update. 07/01/26:- Plan publish additional data from two completed INT230-6 studies in H2 2026. 08/11/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.